Farmas USA

jajjajaa...muy bueno.......

Pues por ahí estoy
AMRN -3000
ARNA 0
ACHN +300
THLD +500
HZNP -300
UG +500
IBEX -1000
GNOM -300

sernestor, no metamos al ibex en la lista, porque entonces me pego un tiro.Ojala recuperes esos 1000, por que yo necesitaré algo más que acierto y buena suerte para compensar este mes, que me ha jodido todo el año, lo ganado el pasado y no se si los proximos 10 años.

EXEL:

Exelixis Announces Initiation of Cabozantinib Investigator-Sponsored Trials in Non-Small Cell Lung Cancer and Multiple Myeloma
26 Jul 2012
Trials match tumor molecular characteristics with cabozantinib’s target inhibition profile

SOUTH SAN FRANCISCO, CA, USA I July 26, 2012 I Exelixis, Inc. (EXEL) today announced the initiation of two investigator-sponsored trials (ISTs) of cabozantinib, which simultaneously targets MET, VEGFR2 and RET. Naiyer Rizvi, M.D., a lung cancer specialist at Memorial Sloan Kettering Cancer Center (MSKCC), is conducting a phase 2 clinical trial of cabozantinib in non-small cell lung cancer (NSCLC) patients who have tested positive for gene fusions that activate RET. Anuj Mahindra, MBBS, member of the hematology staff at Massachusetts General Hospital (MGH), is conducting a pilot phase 1 clinical trial of cabozantinib in patients with relapsed or refractory multiple myeloma, a disease for which there is evidence of MET’s role in pathogenesis.

“Exelixis’ IST Program is a critical component of our strategy to evaluate cabozantinib in a broad array of indications while focusing our internal efforts and resources on medullary thyroid cancer and prostate cancer,” said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. “We are pleased to support leading oncologists such as Dr. Rizvi and Dr. Mahindra as they leverage cabozantinib’s target-inhibition profile to address specific cancer indications in which these targets are believed to play a key role. For example, in the case of NSCLC, mounting evidence suggests that the presence of the KIF5B/RET fusion may signify a new molecular subset of the disease. An IST with cabozantinib, a potent inhibitor of RET that has shown strong clinical activity in another RET-driven cancer, is a logical next step in advancing new approaches to treat the disease.”

The phase 2 NSCLC trial is designed to enroll 25 patients with KIF5B/RET or related variant RET fusions in their tumors. These patients will receive a daily 60 mg dose of cabozantinib administered orally. The primary endpoint of the trial is overall response rate. Secondary endpoints include progression-free survival, overall survival, and safety. Investigators will also seek to determine the frequency of KIF5B/RET and related variant RET fusions in patients whose tumors are negative for previously identified oncogenic activating mutations or translocations (including those involving EGFR, KRAS, and ALK).

The phase 1 multiple myeloma trial is designed to assess the safety, tolerability, and preliminary activity of cabozantinib in patients with relapsed or refractory myeloma with bone disease. The first cohort of patients will receive 40 mg of cabozantinib daily. Based on the safety in the first cohort, a second cohort of patients will receive either 20 mg or 60 mg of cabozantinib, administered daily. Safety in the initial dosing cohorts will be used to determine a dose for an expansion phase of the trial consisting of 10 additional patients.

About Cabozantinib

Cabozantinib is a potent targeted therapy that inhibits MET, VEGFR2 and RET. Cabozantinib is an investigational agent that provides coordinated inhibition of metastasis and angiogenesis to kill tumor cells while blocking their escape pathways. The therapeutic role of cabozantinib is currently being investigated across several tumor types. MET is upregulated in many tumor types, thus facilitating tumor cell escape by promoting the formation of more aggressive phenotypes, resulting in metastasis. MET-driven metastasis may be further stimulated by hypoxic conditions in the tumor environment, which are often exacerbated by selective VEGF-pathway inhibitors. In preclinical studies, cabozantinib has shown powerful tumoricidal, antimetastatic and antiangiogenic effects, including:

Extensive apoptosis of malignant cells
Decreased tumor invasiveness and metastasis
Decreased tumor and endothelial cell proliferation
Blockade of metastatic bone lesion progression
Disruption of tumor vasculature

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib (XL184), its most advanced product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, broadly-active, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at www.exelixis.com.

Puf, vaya dia q os ha tocado hoy. Yo vendí HZNP a 8,1 porque la vi alta, pero este descenso no me encaja. El lunes entro si sigue a ese nivel.
Y recordad: la apadrina Enola.

Saludos.

Solrac....Enola habló de ella en 4$ y antes de la PDUFA......creo que ahora la historia es diferente!!

Saludos

En efecto que ha cambiado. Antes no se le había aprobado y ahora sí.

Ahora lanzo una pregunta al vuelo!!!

Se habla mucho de buy&out, sobre OMPI,ATRS.GNOM,AMRN,ARNA,etc..pero conocéis algún buy&out que se haya hecho y haya merecido la pena?? no sera toda esa info bulos para calentar valores y dejarnos pillados a muchos??

Por ejemplo, en ARNA y AMRN que son las que llevo....mañana mismo sale una mala noticia sobre belviq o etc y se va todo a la mierda!!!

Please...no leerlo como un comentario negativo sino como una pregunta que me ronda después de ver los ejemplos de HZNP,AMRN y ARNA.....no llego a entender porque con el potencial de venta que tiene sus fármacos no han sido ya buy&out o porque bajan....

Saludos